On August 3, 2018, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. and Genhouse Bio (Suzhou) Co., Ltd. held the cooperation signing ceremony of innovative fully human monoclonal antibody project in Sanyou Biopharmaceuticals.

Genhouse Bio officially signed a contract with Sanyou Biopharmaceuticals.

In attendance of the ceremony are Dr. Kuifeng Wang, CEO of Genhouse Bio, Dr. Guojun Lang, CEO of Sanyou Biopharmaceuticals, and key project team members.  At the ceremony, Dr. Kuifeng Wang shared Genhouse Bio’s development process, vision and mission since its establishment and emphasized its goal and and the importance of this project in cooperation with Sanyou Biopharmaceuticals. Dr. Guojun Lang also introduced the development process of Sanyou Biopharmaceuticals and emphasized the significance of this cooperation with Genhouse Bio focusing on the innovation and R & D of small molecule drugs and Sanyou Biopharmaceuticals  on the innovation and R & D of giant molecule drugs.

After signing, with more in-depth communications and discussions on the project objectives, technical route, research contents and methods, time nodes, breakthrough of difficulties, division of labor, management mechanism, risk control, etc., both parties believe that this cooperation marks the beginning of a strategic cooperation based on the principles of mutual trust, fairness, justice and win-win cooperation.  Both parties are committed to playing their full respective advantages and joining their effort in promoting the R&D of a series of anti-tumor candidate drugs.

Group photo of representatives of both parties

Genhouse Bio

Located in Suzhou Industrial Park, Genhouse Bio (Suzhou) Co., Ltd. is a leading enterprise in science specializing on the R&D of original anti-tumor drugs and high-quality innovative drugs, targeting the much-needed clinical needs worldwide.  It focuses on medical services for cancer patients and R&D of new drugs based on "precision medicine" and engages in the development of new tumor immunotherapy drugs with personalized characteristics and clinical testing methods for tumor markers by combining the giant and small molecules.  Genhouse Bio’s main customers  include large-scale 3A hospitals (medical services for cancer patients) and large to medium-sized pharmaceutical companies (new drug technology/product transfer). It aims to develop into an innovative high-tech biopharmaceutical enterprise integrating service, R&D, production and sales.